• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Stronger Q2 Results and Higher 2026 Outlook Might Change The Case For Investing In DexCom (DXCM)

    Simply Wall St·08/11/2026 01:29:11
    Listen to the news
    • In July 2026, DexCom, Inc. reported second-quarter results showing higher sales of US$1,308.4 million and increased net income of US$249.1 million compared with the prior year, and also raised its full-year 2026 revenue guidance to a range of US$5.18 billion to US$5.25 billion.
    • The combination of stronger quarterly earnings and higher full-year revenue guidance suggests management’s confidence in DexCom’s current operating momentum and demand for its continuous glucose monitoring systems.
    • With DexCom lifting its full-year revenue outlook, we’ll now examine how this upgraded guidance affects the company’s existing investment narrative.

    Find 52 companies with promising cash flow potential yet trading below their fair value.

    DexCom Investment Narrative Recap

    To be comfortable owning DexCom, you need to believe continuous glucose monitoring can stay central to diabetes care and that DexCom can defend its premium position despite recalls, leadership transition and rising competition. The Q2 beat and higher 2026 revenue guidance support the near term catalyst of broadening adoption, especially in type 2 and non intensive insulin users, but they do little to reduce key risks around potential CMS pricing pressure and execution through the CEO handover.

    The most relevant recent development here is DexCom’s Q2 2026 earnings release, which paired higher sales of US$1,308.4 million and net income of US$249.1 million with the revenue guidance upgrade to US$5.18 billion to US$5.25 billion. Together, these results reinforce that the current demand backdrop for DexCom’s CGM portfolio, including G7 and newer offerings like Stelo and Flex, remains supportive of the adoption driven catalyst investors are focused on.

    Yet despite the stronger outlook, investors should still be aware of the risk that potential CMS competitive bidding and pricing pressure could...

    Read the full narrative on DexCom (it's free!)

    DexCom's narrative projects $6.8 billion revenue and $1.5 billion earnings by 2029. This requires 11.1% yearly revenue growth and a roughly $500 million earnings increase from $999.7 million today.

    Uncover how DexCom's forecasts yield a $91.64 fair value, a 5% upside to its current price.

    Exploring Other Perspectives

    DXCM 1-Year Stock Price Chart
    DXCM 1-Year Stock Price Chart

    Some of the lowest ranked analysts were assuming revenue of about US$6.5 billion and earnings of roughly US$1.2 billion by 2029, so compared with concerns about slower type 2 adoption and uncertain CMS coverage, their view sets a much more cautious bar that this stronger Q2 update may or may not ultimately shift.

    Explore 5 other fair value estimates on DexCom - why the stock might be worth just $91.64!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your DexCom research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free DexCom research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DexCom's overall financial health at a glance.

    No Opportunity In DexCom?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.